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Background: OmCI is an ectoparasite-derived anti-inflammatory protein that binds LTB4 and prevents complement C5
activation.
Results:TheC5 andLTB4 binding activities ofOmCI are functionally and structurally independent, andOmCI potently inhibits
immune complex-induced acute lung injury (IC-ALI).
Conclusion: LTB4 and C5 activation by complement contribute equally to the pathology of IC-ALI.
Significance: Dual inhibition of these mediators should be considered for treatment of IC-dependent diseases.
Molecules that simultaneously inhibit independent or co-de-
pendent proinflammatory pathways may have advantages over
conventionalmonotherapeutics.OmCI is a bifunctional protein
derived fromblood-feeding ticks that specifically prevents com-
plement (C)-mediated C5 activation and also sequesters leuko-
triene B4 (LTB4) within an internal binding pocket. Here, we
examined the effect of LTB4 binding on OmCI structure and
function and investigated the relative importance of C-medi-
ated C5 activation and LTB4 in a mouse model of immune
complex-induced acute lung injury (IC-ALI). We describe
two crystal structures of bacterially expressed OmCI: one
binding a C16 fatty acid and the other binding LTB4 (C20).
We show that the C5 and LTB4 binding activities of the mol-
ecule are independent of each other and that OmCI is a
potent inhibitor of experimental IC-ALI, equally dependent
on both C5 inhibition and LTB4 binding for full activity. The
data highlight the importance of LTB4 in IC-ALI and activa-
tion of C5 by the complement pathway C5 convertase rather
than by non-C proteases. The findings suggest that dual inhi-
bition of C5 and LTB4 may be useful for treatment of human
immune complex-dependent diseases.
The immune response depends upon coordinated release
and orchestration of diverse mediators. Molecules that simul-
taneously inhibit mediators that have independent or co-de-
pendent proinflammatory effects may have advantages over
conventional therapeutics such as mAb, which normally target
single components of the immune system. Possible advantages
of targeting more than one pathway include higher specificity,
lower effective dose (1), and the ability to counteract compen-
sation mechanisms within biological networks (2, 3).
The 17-kDa lipocalin Ornithodoros moubata complement
inhibitor OmCI (4), originally isolated from an ectoparasitic
tick (Acari), is a bifunctional protein that may have such ther-
apeutic advantages. It captures the proinflammatory eico-
sanoid leukotriene B4 (LTB4)8 within an internal binding cavity
(data presented herein) and also prevents complement (C)-me-
diated activation of C component 5 (C5) in a wide range of
mammalian species including humans (5). By binding directly
to C5 in the vicinity of the C5-C345C domain OmCI prevents
cleavage of C5 by the C5 complement convertases, thereby pre-
venting release of anaphylatoxin C5a and formation of the
terminal 5b-9 C complex (TCC) (6–8). OmCI therefore cir-
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cumvents the effects of the TCC, and the cell surfaceG protein-
coupled receptors activated by LTB4 (BLT1 and BLT2 recep-
tors) and C5a (C5aR). OmCI may also prevent activation of the
non-G protein-coupled C5L2 receptor for C5a. The function,
and even the cellular location, of C5L2 is subject to ongoing
debate with both pro- and anti-inflammatory activities
described (9).
The established downstream effects of the TCC and C5aR,
BLT1, and BLT2 signaling are numerous and interlinked. LTB4,
derived like all eicosanoids from arachidonic acid (AA), and
activated C5 both have rapid and vital roles in the initiation and
coordination of the early inflammatory and adaptive immune
responses (reviewed inRefs. 10–14). Among other effects, TCC
formation on self-cells induces release of inflammatory media-
tors including IL-6, synthesis of AA derivatives, transendothe-
lial migration of polymorphonuclear leukocytes, and produc-
tion of active oxygen metabolites (reviewed in Ref. 15). Both
C5a and LTB4 rapidly recruit and activate granulocytes (in par-
ticular neutrophils) and monocytes and trigger oxidative burst
and degranulation (14–17), resulting in the release of numer-
ous preformedproinflammatory and vasoactivemediators (his-
tamine, serotonin, tryptase, and defensins) and proteases that
can generate C5a independently of C (18, 19). These actions
stimulate the production of proinflammatory cytokines (IL-1,
IL-2, IL-6, IL-8, and TNF), chemokines (eotaxin, RANTES,
andMIP2), growth factor (TGF), LTB4, and other eicosanoids
that augment and prolong tissue inflammation (20, 21). C5a
alone induces vasodilation and smoothmuscle cell contraction,
whereas both C5a and LTB4 increasemicrovascular permeabil-
ity (10, 13). LTB4 amplifies the neutrophil chemotactic effect of
C5a in inflammatory processes, and conversely, the release of
AA and synthesis of LTB4 can be stimulated by both TCC and
C5a (10, 15, 22–24).
Marketed therapies target C5 or leukotrienes. C is the focus
of much recent drug research and development (10, 25), and a
humanized anti-C5 mAb (eculizumab) successfully treats noc-
turnal paroxysmal hemoglobinuria (26). Eculizumab is in clin-
ical trials for the treatment of a variety of other pathologies
including atypical hemolytic uremic syndrome and kidney
transplant rejection (60, 61). Therapies targeting leukotrienes
are more advanced (27). Glucocorticoids inhibit the release of
AA (28).Other drugs approved for treatment of chronic asthma
target leukotrienes directly by inhibiting the 5-LOX enzyme
required for LTB4 and cysteinyl leukotriene (cysLT) synthesis
(zileuton (29)) or antagonize the high affinity receptorCysLT1R
that mediates most of the effects of the cysLTs (zafirlukast and
montelukast (30)). No drug that acts specifically on LTB4 or its
receptors has yet reached the market, but many are in develop-
ment (31). The effect of the combined inhibition of C5 and
LTB4 has not been reported.
Given the direct and indirect interactions between C and
LTB4 and the efficacy of marketed drugs targeted at C5 and
LTs, we hypothesized that combined inhibition of these com-
ponents might potently inhibit inflammation. Here, we exam-
ined the effect of LTB4 binding on structure and function of
OmCI and investigated the relative importance of C-mediated
C5 activation and LTB4 in amousemodel (9, 32–37) of immune
complex-induced acute lung injury (IC-ALI).
EXPERIMENTAL PROCEDURES
Materials—[5,6,8,9,11,12,14,15-3H(n)]LTB4 (lot 3589956;
total activity 5 Ci or 185 kBq; specific activity 190 Ci/mmol)
was from PerkinElmer Life Sciences. Fatty acid ELISA kits were
fromAssayDesigns, Inc. TheC5a assay kit was fromDRGDiag-
nostica (catalog No. RE59292). All surface plasmon resonance
(SPR) reagents were from Biacore (Uppsala, Sweden). Sheep
RBC were from Tissue Culture Services. Hemolysin, pooled
normal human sera, GVB2, and human thrombin (catalogNo.
T6884) were from Sigma. Guinea pig serum and the control
proteins RaHBP2 (Rhipicephalus appendiculatus histamine-
binding protein 2) and OmCLI (O. moubata cysteinyl leukotri-
ene inhibitor) were derived in-house. Human C5 (hC5) was
purchased from Calbiochem (catalog No. 204888). The 5-li-
poxygenase-activating enzyme inhibitor MK886 was pur-
chased from Tocris Bioscience (Bristol, UK), and LTB4,
leukotriene C4 (LTC4), 12(S)-hydroxyeicosatetraenoic acid
(12(S)-HETE), and AA were bought from Cayman Chemical
(Ann Arbor, MI) and Biomol International (Exeter, UK).
Recombinant OmCI—Soluble bacterially expressed OmCI
(bOmCI) was manufactured using the proprietary technology
of Wacker GmbH (38). Escherichia coli strain WCM105 con-
taining a plasmid for expression and secretion of OmCI was
cultivated in a 30-liter bioreactor (type Biostat C-20; Sartorius
AG, Melsungen, Germany). Fermentation was performed at
30 °C in a mineral salt medium including trace elements, yeast
extract, and phytone at pH 7.0 under aerobic conditions with a
continuous glucose feed. Prior to inducing expression with
IPTG, the temperature was dropped to 20 °C. Approximately
36 h after induction, the supernatant was harvested by centri-
fugation (CEPA Z41, Padberg GmbH, Germany) and filtered
using a 0.45-m membrane filter (Sartopure PP2) and then a
0.2-m membrane filter (Sartopore 2HF). OmCI was purified
from the supernatant as described (7) with a final additional
chromatographic step in which the active fractions were
adjusted to 2 M ammonium sulfate and then loaded onto phe-
nyl-Sepharose (GE Healthcare) and eluted using a 2–0.5 M
ammonium sulfate gradient. Active fractions were dialyzed
against PBS, analyzed by denaturing SDS-PAGE, and concen-
trated to 8.4 mg/ml by ultrafiltration. A predicted A2800.1%, 1 cm
of 1.3 was used to estimate the protein concentration. The pure
protein (94% by RP-HPLC (supplemental Fig. S1) had a final
yield of 0.4 g/liter of fermentation broth. The identity and
activity of the protein were confirmed by ESI-Q-TOF MS and
by inhibition of a classical complement pathway assay used in
accordance with the manufacturer’s instructions (CH50 Eq
ELISA from Quidel). The experimentally estimated Mr
(16,779.0 g/mol) matched the calculatedMr of 16,779.5 g/mol.
GC-MS Analysis of Fatty Acids from Recombinant bOmCI—
Extraction and analysis of fatty acids from the recombinant
protein was performed as described (6). Mass spectrometric
analysis was performed on a Trace MS (Thermo Finnigan,
D-63329, Egelsbach, Germany) equipped with fused silica All-
tech EC5 (D-82008, Unterhaching, Germany) capillary (15m
0.25 mm, 0.25 m) using helium at 1.5 ml min1 as the carrier
gas.
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Preparation of LTB4-saturated OmCI (bOmCI-LTB4)—
bOmCI (4.5 mg) was incubated with 2 ml of LTB4 (50 ng/l
stock in ultrapure ethanol) in 39 ml of PBS, pH 7.2, at room
temperature with shaking for 10 min. This 1:1.1 molar ratio
mixture was concentrated to 200l in a 5-kDa cut-off Vivaspin
ultrafiltration device (Sartorious). The retentate was washed
with 30 ml of PBS, pH 7.2, and reconcentrated to 200 l. In
parallel, the same amount (4.5 mg) of bOmCI was incubated
with 2ml of ultrapure ethanol in 39ml of PBS and then washed
and concentrated as described.
Measurement of Eicosanoid Binding by Enzyme Immu-
noassay—Correlate-EIATM kits (Assay Designs, Inc.) for solu-
tionmeasurement of LTB4, thromboxaneB2 (TXB2), and cysLT
were used. To examine direct binding, 0.1–30 g of pure
OmCI, OmCI saturated with LTB4, RaHBP2 (histamine bind-
ing), and OmCLI (cysteinyl leukotriene binding) were incu-
bated with 150 l of the eicosanoids conjugated to alkaline
phosphatase (AP). After 20 min of shaking (500 rpm) at room
temperature, free eicosanoid-AP was detected by mixing the
lipocalin-eicosanoid solution with anti-eicosanoid-specific
polyclonal rabbit Ab and adding the solution to a plate coated
with goat anti-rabbit Ab. After a 2-h incubation, the plate was
washed in accordance with the manufacturer’s instructions; at
this stage the tick lipocalins including those bound to eico-
sanoid-AP were washed away. Anti-eicosanoid Ab bound to
AP-labeled fatty acids was detected by addition of substrate.
The results for each lipocalin were compared with PBS
controls.
UV Absorption Spectroscopy of bOmCI Bound to LTB4—
bOmCI and LTB4 in ethanol were mixed in PBS at molar ratios
of 0:1, 0.03:1, 0.06:1, 0.0125:1. 0.25:1, 0.5:1, 1:1, 2:1, 4:1, and 8:1
and incubated for 5 min at room temperature. UV absorption
spectra (200–400 nm) were recorded using a Nanodrop
ND-1000 spectrophotometer. The average spectrum (five rep-
licates) for each protein dilution with ultrapure ethanol but
without LTB4 was subtracted from the average spectrum for
each protein dilution in the presence of LTB4. The same assay
was undertaken using a 4:1 molar excess of RaHBP2, OmCLI,
andOmCI saturatedwith LTB4. Spectroscopy of LTB4with and
without OmCI was also undertaken in the presence of a large
molar excess of AA (60) or 12(S)-HETE (40). The average
spectrum (five replicates) for each protein dilution with AA or
12(S)-HETE but without LTB4was subtracted from the average
spectrum for each protein dilution in the presence of LTB4
mixed with excess AA or 12(S)-HETE.
bOmCI Crystallization, Data Collection, and Structure De-
termination—bOmCI and bOmCI-LTB4 crystals were grown
by vapor diffusion in 400 nl of sitting drops at 20 °C. The crys-
tallization dropswere obtained bymixing 0.2l of protein solu-
tion with 0.2 l of the crystallization screen and were equili-
brated against 100 l of mother liquor.
For bOmCI, screens were set up using a TECAN robot
(Tecan Group Ltd.). Initial crystallization screens using the
molecular dimensions structure screens were set up with
bOmCI at 65 mg/ml. Initial crystals grew in conditions 23, 33,
and 37 of MD Structure Screen 1; the best crystals grew after
setting up repeats of condition 33 (30% PEG 4000, 0.2 M mag-
nesium chloride, and 0.1 M Tris, pH 8.5).
For bOmCI-LTB4, bOmCI loaded with LTB4 (see “Experi-
mental Procedures”) was concentrated to 25 mg/ml in Tris-
HCl, pH 7, 30 mM NaCl. Screens were set up using an Oryx-
Nano robot (Douglas Instruments Ltd., UK). Initial
crystallization screens usingHampton Research crystal screens
were set up with a bOmCI-LTB4 mix in 1:1 molar ratios (see
above for concentration). Initial crystals grew in conditions 14
and 22 of the Hampton Research Crystal Screen HT; better
crystals were grown after screening around condition 22 (21%
PEG 4000, 0.2 M sodium acetate, 0.1 M Tris, pH 8.4).
FIGURE 1. OmCI binds LTB4. A, bOmCI (5 g) competes with LTB4-specific
polyclonal Ab for binding to LTB4 but does not compete for LTC4 or TXB2.
Negative control was PBS only. Tick lipocalin protein controls were 5 g of
OmCLI (mass, 16.9 kDa) and 5g of RaHBP2 (mass, 20.4 kDa). Shown are four
replicatesper sample fromthree independent experiments (95%CI).B, detec-
tion of LTB4 binding to OmCI shown by red shift in the characteristic absorb-
ance spectra of the leukotriene. Peak absorbance shifts from 271 nm with
shoulders at 261 and 281 nm for LTB4 only (i.e.molar ratio 0:1) to 277 nmwith
shoulders at 267 and 287 nm at LTB4 to bOmCImolar ratios of 1:1 and higher.
For clarity, absorbance values measured at 1 nM intervals are shown as
smoothed lines. C, LTB4 binding causes amobility shift in bOmCI by Coomas-
sie Blue-stained native PAGE. The molar ratio of bOmCI to LTB4 is shown
above each lane.
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For bOmCI, a 1.9 Å x-ray diffraction data set was collected
from a crystal (orthorhombic P212121, a 44.4 Å, b 51.9 Å,
c 68.40 Å, 1 molecule/asymmetric unit) on beamline ID14-2
at the ESRF. For bOmCI-LTB4 a 1.9 Å x-ray diffraction data set
was collected from a crystal (monoclinic P21, a 41.76 Å, b
112.81 Å, c 62.40 Å,  101.89 degrees, 4 molecules/asym-
metric unit) on beamline BM14 at the ESRF. All x-ray data
integration and scaling were done using the computer pro-
grams Mosflm (39) and Scala (40). Supplemental Table S1
shows the crystallographic data collection and processing sta-
tistics. Both structures were phased by molecular replacement
with the computer program CCP4-Phaser, built in Coot (41),
and refined in Buster-TNT (42) using alternating cycles of full B
refinement and TLS refinement, with one TLS body per chain.
Supplemental Table S2 contains the final crystallographic
refinement data and statistics. The yeast-expressed yOmCI
coordinates (PDB accession code 2CM4) were used as a search
model for bOmCI. The model for the bound palmitoleic acid
was built in the residual electron density once themodel for the
protein had been completed. For bOmCI-LTB4, the search
model was the bOmCI structure stripped of the ligand. The
model for the bound LTB4 was built in the residual electron
density once the model for the protein had been completed.
The initial stages of refinement implemented non-crystallo-
graphic symmetry restraints, which were released in the final
cycles. The structures were deposited in the Protein Data Bank
and have accession codes 3ZUI and 3ZUO.
Surface Plasmon Resonance—Measurements were con-
ducted on a Biacore 3000 instrument. 600–1000 resonance
units of bOmCI or 200–300 resonance units of bOmCI-LTB4
(which coupled less efficiently than bOmCI) were immobi-
lized by amine coupling at pH 4.5 to separate CM5 sensor
chips as recommended by Biacore. A control channel was
mock coupled with buffer. All experiments were performed
at 25 °C in 10 mMHEPES, pH 7.4, 150 mMNaCl, 3 mM EDTA,
and 0.005% surfactant P20 with various concentrations of
hC5 with and without 10 nM LTB4. Analyte solutions were
passed through the flow cells sequentially at a flow rate of 40
l/min. The chip surface was regenerated using 10 mM gly-
cine, pH 1.5, between each injection. Kinetic parameters
were evaluated in accordance with the manufacturer’s
instructions.
Classical Hemolytic Assay—Sensitized sheep erythrocytes
were prepared in GVB2 buffer. Assays were carried out
using 50 l of 1:320 GVB2 diluted guinea pig serum and 50
l of 2  108 activated erythrocyte cells ml1. This was the
maximum serum dilution (1:640 final) that gave100% lysis
without inhibitor after 30 min of incubation. The GVB2
buffer was supplemented with a 2-fold molar excess of LTB4
to bOmCI. bOmCI or RaHBP2 control protein diluted in PBS
FIGURE 2. Structure of bOmCI with and without LTB4 in the binding pocket. A and B, schematic representations of the bOmCI molecule from the LTB4
cocrystal. Blue to red, from N to C terminus. The cysteine side chains and LTB4 ligand are shown in stick representation, with the ligand carbon atoms colored
yellow and the oxygen atoms red. ViewsA and B are rotated forward by 90° around the horizontal axis.B-C andH-3 loops, which undergo conformational
changes, are labeled. For the strand and helix labels see Ref. 6. C andD, representation ofmost significant, but still minor, conformational differences between
bOmCI-palmitoleic acid and bOmCI-LTB4. C, the conformation of B-C loop-(61–70) changes with ligand size. Green, bOmCI-LTB4 complex; blue, bOmCI-
palmitoleic acid complex; loop-(61–70), which swings out to better accommodate LTB4, is shown in darker shades in bothmolecules. The fatty acid ligands and
Pro-61, the residue mediating the change in structure and contacting the ligand, are in stick representation. The yOmCI-ricinoleic acid complex is not shown,
but its loop aligns with the conformation seen in the bOmCI-palmitoleic acid complex. D, His-117 and the H-3 loop (residues 135–141) are coupled. Green,
bOmCI-LTB4 complex; yellow, yOmCI-ricinoleic acid (PDB accession code 1CM4). The H-3 loop (residues 135–141) is in darker shades. His-117, in which the
side chain conformation accompanies the loop rearrangement, is represented in sticks.
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was added last (5 l each), and reactions were incubated at
37 °C for 30 min. Reactions were centrifuged (12000  g for
5 s) and hemolysis measured at 412 nm. Percent lysis was
calculated using the absorbance value for 100% cell
lysis caused by adding 50 l of water to 50 l of erythrocyte
cells.
Measurement of LTB4 Binding Using Radioligand—A 1:2
molar ratio of bOmCI and hC5 were incubated in PBS at
room temperature for 10 min to form the bOmCI-hC5 com-
plex. Formation of the complex was confirmed by native
PAGE gel shift (see Ref. 8 for example). Equal amounts
bOmCI-hC5 or bOmCI alonewere serially diluted in 75l of PBS
before adding 75 l of PBS containing 24,000 cpm 3H-LTB4.
Following shaking incubation (3 h, 500 rpm, room temperature),
samples were centrifuged at 8000 g for 2 min, and the radioac-
tivity remaining in solutionwasmeasured on aWallac 1217Rack-
beta liquid scintillation counter after transferring 20 l of the
supernatant to4mlofBeckmanReadyValue scintillationmixture.
PBS only and serial dilutions of RaHBP2 and hC5 in PBS were
negative controls.
Thrombin-mediated Cleavage of C5—One g of hC5 and 2.5
NIH units of human thrombin were incubated in PBS at 37 °C
for 1.5 h, alone, together, andwith orwithoutOmCI or protease
inhibitor mixture (Sigma, catalog No. P8340). 1, 10, and
100molar excess of OmCI to hC5 were used. Following incu-
bation, human thrombin was inactivated (65 °C for 4 min), and
free C5a was detected using a DRGDiagnostica enzyme immu-
noassay kit (catalog No. RE59292).
Immune Complex Acute Lung Injury Model—All animal
experiments were approved by the CNRS institutional ani-
mal research committee and complied with the French Gov-
ernment’s ethical and animal experiment regulations. C57/
BL6 mice, male, about 8 weeks old and with a body weight of
about 25 g, were dosed intranasally with 150 g of chicken
anti-ovalbumin IgG (anti-OVA) together with the drug of
interest (bOmCI, bOmCI-LTB4, RaHBP2 orMK886) in 40 l
of saline. Immediately thereafter, immune complex in the
lung was induced by injecting 300 g of OVA and 0.3% Evans
blue into the tail vein. Experiments were performed three
times with groups of six animals in each treatment. MK886
was administered at 1 mg/kg by gavage and LTB4 by intra-
nasal instillation. In the latter experiments, OmCI and
RaHBP2 were administered immediately before LTB4. At 4 h
after OVA or LTB4 administration, mice were killed, BAL
was performed, and lungs were perfused with an isotonic
solution and then excised. Cells in BAL were counted, and
differential staining was performed using Diff-Quik. Vascu-
lar leakage was quantified by protein concentration in the
bronchoalveolar space, and Evans blue was measured in BAL
supernatant by absorbance at 460 nm. The excised lung was
fixed in 4% buffered formaldehyde for H&E, andmicroscopic
FIGURE 3. Details of ligand binding. A, bOmCI-LTB4 1.9 Å Fo Fc residual
electron density contoured at the1.0  level, is computed without mod-
eling of the ligand. The final model for the LTB4 ligand is shown with
carbon (yellow) and oxygen (red) surrounded by the OmCI pocket residues
(carbon, green; oxygen, red; nitrogen, blue; and sulfur, yellow); this picture
was produced with the program PyMOL (44). B, schematic representation
of the bOmCI residues forming hydrogen bonds (with distances in Å) and
non-bonding hydrophobic contacts to LTB4 (upper panel) and palmitoleic
acid (lower panel). These pictures were producedwith the program LigPlot
(45).
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lesions (endothelial cell damage, inflammatory cell recruit-
ment, and erythrocytes in the alveolar space) were assessed
using a semiquantitative score (0–3) by two independent
observers. C5a in the BAL supernatant was measured using
the C5a micro MTPL EIA kit in accordance with the manu-
facturer’s instructions (DRG Diagnostics GmbH).
StatisticalAnalyses—Thedataarepresentedas themeanS.D.
or 95% CI as indicated in the figure legends. The significance of
differences between two groupswas determined by one-way anal-
ysis of variance (non-parametric test) usingGraphPad Prism soft-
ware, version 5, or in R using Tukey’s multiple comparison of
means. Plots of the residuals were used to confirm the homosce-
FIGURE 4. C5 and LTB4 binding activities of OmCI are independent. A, LTB4 (2-fold molar excess) has no effect on the classical C pathway inhibitory
activity of bOmCI assayed by hemolysis. Bars show 95% CI (n 4 for each data point). B, spectroscopy showing that LTB4 remains bound (characteristic
red-shifted spectrum) to bOmCI in low pH (5.5 and 4), 10 mM sodium acetate buffers. C and D, SPR measurement of binding between bOmCI and human
C5 (hC5) in the absence (C) and presence (D) of LTB4. Curves were fitted using a 1:1 Langmuir model (shown in black). Mean KD and chi-squared values
are shown with their standard deviation calculated from 15 replicates. Replicates were performed over a minimum of two independent experiments.
The RUs in D are lower than in C because less bOmCI-LTB4 than bOmCI coupled to the sensor surface. E and F, binding of radiolabeled LTB4 by bOmCI
alone and in complex with hC5. E, plot showing that ligand binding is saturable. RaHBP2 and hC5 alone do not show saturable binding, and cpm values
are equivalent to PBS only (not shown). Raw data shown (n 2 for each data point) are representative of three independent experiments. The highest
concentration of OmCI-hC5 (i.e. 10000 nM) was not assayed, as the amount of hC5 required was prohibitively expensive. F, plot showing interaction of
hC5 with bOmCI has no effect on the binding kinetics to LTB4. The data are representative of two independent experiments (n 2 for each data point)
and show cpm values after subtraction of average cpm (n 16) of the negative control (RaHBP2). Logarithmic regression line functions are: bOmCI, y
134.67 ln(x)  521.6, R2 0.98; bOmCI-hC5, y  132.87 ln(x)  479.2, R2 0.97.
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dasticity of the data. Statistical significance was reported if p was
0.05.
RESULTS
OmCI Binds a Variety of Unbranched Fatty Acids, but Its
Preferred Ligand Is LTB4—We reported previously that OmCI
expressed in yeast (yOmCI) is bound to ricinoleic acid
(C18H34O3) and speculated that the natural host ligand bound
by OmCI when secreted into the tick feeding site might be a
proinflammatory eicosanoid (6). This was confirmed later
using homologues of OmCI derived from other tick species
(43). Solvent extraction and GC-MS analysis of the highly puri-
fied bOmCI used in this study (supplemental Fig. S1) showed
that C16:1 cis-palmitoleic acid (C16H30O2) was the dominant
(64%) fatty acid in the binding pocket of bOmCI, with various
other C16–C18 linear fatty acids present in lower proportions
(supplemental Fig. S2). Preferential binding to LTB4was shown
using an enzyme immunoassay in which bOmCI sequestered
LTB4, preventing the AP-conjugated eicosanoid from interact-
ing with specific capture antibodies of unknown, but presum-
ably high, avidity (Fig. 1A). In the same assay, bOmCI did not
show evidence of binding to the cyclic eicosanoid TXB2 (a sta-
ble derivative of TXA2) or to LTC4, which has amino acids
conjugated to carbon 6 (C6) of the fatty acid chain (Fig. 1A). The
positive and negative control tick-derived recombinant lipoca-
lins bound LTC4 only (OmCLI- and cysLT-specific) or none
(RaHBP2- and histamine-specific) of the fatty acids tested (Fig.
1A).
The distinctive absorption spectrum of LTB4 was exploited
to show that when bound to OmCI, the UV maxima of LTB4
exhibits a6 nm bathochromic (red) shift to 277, 267, and 287
nm (Fig. 1B). The shift was complete at a 1:1 molar ratio of
FIGURE 5. OmCI inhibits IC-ALI. A, OmCI (100 g) reduces neutrophils in BALF and lung (myeloperoxidase activity) and prevents hemorrhage, protein and
Evan’s Blue (EB) leak, and edema. B, dose-response effect of OmCI (50, 100, and 200g/mouse) on neutrophil recruitment. All treatment groups except saline
(NaCl)weredosed intranasallywith chicken anti-OVA IgGwithorwithoutOmCI. All groups then receivedOVAby injection into the tail vein. Lung inflammation
was evaluated 4 h after induction of IC. The mean values S.D. of a representative study are given (n 6 mice/group).
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OmCI to LTB4. Dispersion interactions between the conju-
gated leukotriene and nearby amino acids cause the shift, which
is consistent with the triene chromophore of LTB4 being com-
pletely encompassed byOmCI. Spectral shifts in LTB4were not
seen when using OmCLI or RaHBP2 (supplemental Fig. S3A).
The absorption intensity and bathochromic shift was not
altered by a large molar excess of AA (60) or 12(S)-HETE
(40), neither of which has triene chomophores, indicating
that OmCI is highly specific for LTB4 (supplemental Fig. S3B).
LTB4 binding by bOmCI-palmitoleic acid, but not yeast-ex-
pressed yOmCI-ricinoleic acid, altered the proteinsmobility by
native PAGE (Fig. 1C); the shift was complete at a 1:1.5 molar
ratio ofOmCI to LTB4. This encouraged us to examinewhether
LTB4 induces conformational changes in OmCI that affect its
C-inhibitory function.
Structural Analysis of bOmCI and bOmCI-LTB4—We ob-
tained two crystal structures of bOmCI, one in complex with
palmitoleic acid and one in complex with LTB4 (PDB accession
codes 3ZUI and 3ZUO). Both show the same overall structure
as yOmCI-ricinoleic acid (PDB accession code 2CM4); root
mean square deviation C 0.61 and 0.63 Å for the palmitoleic
acid and LTB4 complexes, respectively. Fig. 2, A and B, shows
orthogonal views of bOmCI in complex with LTB4. The main
ligand-dependent structural difference with respect to the
yOmCI-ricinoleic acid crystal structure is the position of the
loop B-C (residues 61–70), which pushes in/out to accom-
modate a smaller/larger ligand (see Fig. 2C). This movement is
mediated by Pro-61, the residue at the bottom of the ligand
pocket. The other main locus of structural variability in the
bOmCI and yOmCI structures is the conformation of the
H-3 loop (amino acids 132–142), shown previously to be
required for C5 inhibition (43), which in both complexes of
bOmCI swings inward, with the concomitant flip of the side
chain of His-117 (Fig. 2D). However, the chemical nature of the
ligand in the pocket bears no relationship to the conformation
of the H-3 loop, as the loop was observed in both conforma-
tions in different copies of the yOmCI-ricinoleic acid complex
(6).
The three ligands all bind with their carboxylic acid head at
the solvent-exposed brim of theOmCI pocket, hydrogen bond-
ing to the side chains of Arg-54, Thr-85, andTrp-87 (see Figs. 2,
A and B, and 3). All ligands fit into the L-shaped pocket, with
the kink at positionC12 of LTB4, ricinoleic acid, and palmitoleic
acid (Fig. 3). Hydroxylation at this position is common to ricin-
oleic acid and LTB4, and both complexes show the -OH group
on C12 forming hydrogen bonds to His-119 and Asp-121 (Fig.
3B, upper panel). Palmitoleic acid lacks the -OH group at this
position, and in that complex the same OmCI residues coordi-
nate a water molecule instead. The ligands are also of different
lengths (C16, C18, and C20, respectively, for palmitoleic acid,
ricinoleic acid, and LTB4); LTB4 fills the pocket completely,
whereas the yOmCI-ricinoleic acid and bOmCI-palmitoleic
acid complexes show a water molecule filling the bottom of the
pocket. Thehydrophobic side chains of Phe-36, Tyr-43, Leu-57,
Gly-59, Pro-61, Leu-70, Val-72, Met-74, Phe-76, Trp-87, Phe-
89, Arg-107, and Trp-133 contact the hydrophobic body of all
three ligands (Fig. 3B). The C9C10 double bond present in
LTB4, but not in palmitoleic or ricinoleic acid, stacks against the
guanidinium head of Arg-107. The same Arg side chain is the
source of the selectivity against cyclic eicosanoids such as TXB2
and TXA2 (43), as it makes the pocket too narrow to accommo-
date cyclic ligands. Gln-105 recognizes the -OH at LTB4 C5.
The OmCI pocket is predicted to be unable to accommodate
-OH at C15 because of the side chains of Phe-36 and Tyr-43, so
the anti-inflammatory eicosanoids 15(S)HETE, lipoxin A4, and
lipoxin B4 are unlikely to be bound by OmCI.
The LTB4 and C5 Binding Activities of OmCI Are Indepen-
dent—The subtle conformational change induced by LTB4
binding may have an effect on the binding of OmCI to C5.
Conversely, C5 binding may change the binding affinity of
OmCI for LTB4. We tested both possibilities by examining the
binding affinity between purified hC5 and bOmCI, with or
without LTB4, and the binding kinetics of OmCI for 3H-labeled
LTB4 in the presence of excess hC5.We first showed that excess
FIGURE 6. OmCI (100 g) inhibits vascular leak, tissue damage, and
inflammation in response to IC. A, OmCI attenuates vascular leak as shown
by blue macroscopic discoloration due to Evans blue leakage. OmCILTB4
signifiesOmCI saturatedwith LTB4before its addition to lung.B, OmCI inhibits
endothelial damage, neutrophil recruitment, and hemorrhage into the alve-
olar space (H&E staining, magnification 100). C, semiquantitative score of
endothelial damage, neutrophil recruitment, and hemorrhage in the lung.
Acute inflammationwasevaluatedat 4h. Representativedata for oneof three
independent experiments are shown (n 6 mice/group). Values are shown
as mean S.D.
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LTB4 had no effect on the potency of bOmCI measured by
classical hemolytic assay (Fig. 4A). Before undertaking SPR
experiments, we confirmed that LTB4 remains bound to
bOmCI at the low pH 4.5 needed to couple the protein to the
chip (Fig. 4B), and where applicable, LTB4 was also included in
the running buffer. The SPR data showed no physiologically
relevant change in hC5 affinity with andwithout LTB4 (Fig. 4,C
and D: KD 1 nM 0.4 without LTB4 and 0.3 nM 0.1 nM with
LTB4). We considered the difference physiologically irrelevant
because the concentration of C5 in human serum is 0.4 M,
and because both KD values were more than 40 times tighter
than this concentration, OmCI would be present as a complex
with C5 whether or not LTB4 was bound. The KD calculated
here by SPR for the interaction between bOmCI and hC5 is
lower (tighter) than that reported previously (7) for yOmCI (KD
18.5 nM) but is characterized by a similar very slow off-rate.
yOmCI has two site-directed point mutations that prevent
hyperglycosylation when expressed in yeast, which may alter
the binding kinetics. Radioligand assays show no alteration of
LTB4 binding in the presence or absence of hC5 (Fig. 4,E andF).
OmCI and preformed OmCI-hC5 complex show equivalent
saturable binding to 3H-LTB4, whereas PBS (not shown but
equivalent to the following twoprotein controls), RaHBP2 (spe-
cific for histamine), and hC5 do not (Fig. 4E). The assay mea-
sured the ability of OmCI to bind 3H-LTB4 and keep it in solu-
tion. Indeed, nomore than 20%of the labeled LTB4 remained in
solution in the negative control samples, whereas more than
50% remained in solution at the higher concentrations ofOmCI
(Fig. 4E), confirming that OmCI binding is needed for solubili-
zation. Because of the low solubility of LTB4 in this assay, asso-
ciation and dissociation constants could not be accurately
derived. However, a comparison of the slope of the logarithmic
regression functions for equivalent concentrations of OmCI
and OmCI-hC5 indicate that the binding kinetics between
LTB4 andOmCI are not altered whenOmCI is in complex with
hC5 (Fig. 4F). In summary, despite a subtle structural change
(Fig. 2C) caused by binding to OmCI, LTB4 has no physiologi-
cally relevant effect on binding between OmCI and C5, and
conversely, C5 binding by OmCI does not hinder or enhance
binding to LTB4. This result is in agreement with previous sug-
gestions that C5 binding and entry of LTB4 to the binding
pocket happen on opposite faces of OmCI (6, 46).
OmCI Ameliorates IC-ALI in Mice—Based on our under-
standing of the binding activities of OmCI, we selected the well
characterizedmousemodel of IC-ALI (33) to test the therapeu-
tic potential of the protein. In this pathology, activation of C
and IgG FcR on effector cells, chiefly alveolar macrophages,
are the dominant initial events following immune complex for-
mation (9, 33). C5a, acting through C5aR signaling, up-regu-
lates the expression of activating FcRIII and down-regulates
inhibitory FcRIIB IgG receptors (35, 36). The FcR imbalance
leads to IC-ALI via alveolar macrophage production of pro-
teases, early response cytokines (TNF and IL-1), and LTs
(predominantly LTB4 (47)), which with C5a increase the
expression of adhesion molecules on vascular endothelial cells,
and induce CXCR1/2 chemokines. These in turn recruit abun-
dant neutrophils that degranulate and release superoxides,
causing inflammation and pulmonary microvascular damage
(9). We first showed that OmCI itself does not induce an
inflammatory response when administered intranasally (Fig.
FIGURE 7.OmCI (100g) neutralizes LTB4-induced inflammation. A, inhibition of leukotriene biosynthesis byMK886 (1mg/kg by gavage) reduces neutro-
phil recruitment inducedby IC-ALI. B, intranasal instillation of LTB4 (1g) induces neutrophil recruitment in the lung,which is inhibited by prior administration
of 2-fold molar excess bOmCI but not by a similar amount of control tick lipocalin histamine-binding protein RaHBP2 (100g). Representative data for one of
three independent experiments are shown (n 6 mice/group). Values are shown as mean S.D.
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5A, compare OmCI and saline). As hoped, bOmCI profoundly
inhibited immune complex-induced neutrophil recruitment to
lung tissue (measured bymyeloperoxidase) and BALF (Fig. 5A).
It also decreased pulmonary microvascular damage, with sig-
nificantly reduced hemorrhage, edema, and protein exudation
to the bronchoalveolar space (Fig. 5A). At 100 g/mouse,
bOmCI reached a plateau for near complete inhibition of
myeloperoxidase activity and neutrophil recruitment to the
alveolar space, with no further decrease at the 200-g dose (Fig.
5B).Macroscopically a distinct capillary leak of Evans blue from
the blood to the lung can be seen, which is attenuated by OmCI
(Fig. 6A). Representative microscopic plates and semiquantita-
tive microscopic evaluation show that bOmCI reduced endo-
thelial cell damage, inflammation, and erythrocyte extravasa-
tion into the bronchoalveolar space (Fig. 6, B and C).
Inhibition of Both C5 Activation by C and LTB4 Binding Is
Needed for Full Inhibitory Effect of OmCI—The proven inde-
pendence of the two binding activities of OmCI enabled us to
investigate the relative importance of LTB4 andC5 activation in
IC-ALI. IC-ALI has been investigated intensively by many
research groups, but the role of LTB4 in IC-ALI has been over-
looked by all but one group (48–50). We therefore first con-
firmed that LTB4 had a functional role in our model. In agree-
ment with the earlier work (48, 49), we found that 4 h after
administration of OVA, LTB4 levels in BAL increase signifi-
cantly (p  0.01) in response to immune complex: saline con-
trol 125.8 pg/ml LTB4 (95% CI, 94.7–156.9 pg/ml, n 8), OVA
243.6 pg/ml LTB4 (95% CI, 292.8–194.45 pg/ml, n  8). Fur-
thermore, administration of MK886, which prevents biosyn-
thesis of LTs, significantly reduced vascular leakage (data not
shown) and inflammation, although the inhibitory effect of
FIGURE 8.OmCI saturatedwith LTB4 (bOmCI-LTB4) is unable tobind addi-
tional LTB4. A, representative absorption spectrum of bOmCI with andwith-
out LTB4 that was used for experiments in mice, crystallization, and SPR.
B, unlike bOmCI, in an enzyme immunoassay bOmCI-LTB4 is unable to com-
pete with LTB4-specific polyclonal Ab for binding to LTB4. Negative control
was PBS only. A 6-fold excess (30 g; see legend for Fig. 1A) of each protein,
including the histamine-binding protein 2 (RaHBP2), was used for each repli-
cate. Four replicates/sample (95% CI) are shown.
FIGURE 9. Saturation of OmCI with LTB4 (OmCI-LTB4) reduces the inhibitory effect of the lipocalin on IC-ALI. Representative data for one of three
independent experiments are shown (n 6 mice/group). Values are shown as mean S.D.
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MK886 was less pronounced than that because of bOmCI (Fig.
7A). Intranasal administration of LTB4 (1 g) caused a signifi-
cant increase in neutrophil recruitment to both the lung tissue
and the bronchoalveolar space (Fig. 7B). Neutrophil recruit-
ment in response to exogenous LTB4was inhibited significantly
by prior administration of bOmCI (in 2-fold molar excess to
LTB4) andwas not inhibited by prior administration of an equal
amount of histamine-specific RaHBP2 (Fig. 7B), suggesting that
OmCI binds LTB4 within the lung.
To examine the importance of each proinflammatory medi-
ator, bOmCI was saturated with LTB4 to form bOmCI-LTB4
(Fig. 8A), and the in vivo activity was compared with parent
bOmCI. We first showed that LTB4-saturated bOmCI cannot
bind additional LTB4 (Fig. 8B) but binds and inhibits C5 as
potently as bOmCI (Fig. 4, A, C, and D). bOmCI-LTB4 signifi-
cantly attenuated all the parameters measured but the anti-
inflammatory effect was less marked than that of bOmCI with
binding capacity for LTB4 (Figs. 9 and Fig. 6A, rightmost lung).
In agreement with its known binding locality remote from the
C5a cleavage site (6, 8),OmCIdoes not prevent thrombinmedi-
ated cleavage of C5a from C5 (Fig. 10A), therefore the inhibi-
tory activity of bOmCI-LTB4 seen in IC-ALI is likely due to
inhibition of C5 activation solely by the C5 convertase and not
by non-C proteases released by activated alveolar macrophages
(18, 19). Both OmCI and OmCI saturated with LTB4 signifi-
cantly decreased the concentration of C5a in BALFmeasured at
4h compared with mice treated with OVA alone, or OVA and
MK886 which prevents LTB4 synthesis but has no direct action
on C5 (Fig. 10B).
DISCUSSION
The tick derived bifunctional protein OmCI significantly
attenuates the symptoms of experimental IC-ALI. Further-
more, inhibition of C-mediated C5 activation and binding of
LTB4 are both required for full potency of OmCI in this animal
model. Our biochemical and structural data show that this is
not mediated by an allosteric effect on OmCI, since C5 has no
effect on LTB4 binding, and although LTB4 increases the bind-
ing affinity of OmCI for C5 measured by SPR this is unlikely to
have any physiological relevance on the inhibitory activity of
the protein in vivo.
The importance of C5a in driving IC-ALI through modula-
tion of FcR signaling in response to immune complex is well
established (33, 35, 36). Current literature on this pathology
emphasizes a dominant role for C5 activation within the alveo-
lar space via non-C5 convertase serine proteases (including
thrombin) released from alveolar macrophages in response to
immune complex (9, 18, 19, 33). However, the significant inhib-
itory activity of bOmCI saturated with LTB4 (bOmCI-LTB4),
which specifically inhibits C5 activation by classical and alter-
native C5 convertases (C3bC2C3b and C3bBbC3b, respec-
tively) and has no effect on C5 activation by non-C proteases,
indicates thatC5 activation directlymediated byC5 convertase,
which is present and active in BALF (51, 52), has a significant
functional role in IC-ALI. This conclusion is supported by ear-
lier work, which showed that thrombin inhibitors significantly
ameliorate IC-ALI in C3/ mice with supernormal levels of
thrombin but not C3/ mice with functional C and normal
levels of thrombin (18). Thus non-C protease-mediated cleav-
age of C5 probably has a secondary role in amplification of C5a
formation in C-sufficient mice.
With the focus onC5a, the importance of LTB4 in IC-ALI has
largely been overlooked by all but one research group (48–50),
although the pivotal role of LTB4 in other models of lung dis-
ease such as LPS-induced ALI- and allergen-induced airway
hypersensitivity is well established (13, 53, 54). Our work sup-
ports the earlierwork showing that LTB4 plays a significant part
in the pathology of IC-ALI (49, 50). Furthermore, we find that
LTB4 inhibition is as important as C convertase C5 activation
for amelioration of symptoms of IC-ALI in the mouse model.
This highlights the co-dependent effects of C5 and LTB4 on
polymorphonuclear leukocyte migration and recruitment and
other proinflammatory processes (9, 13–15, 21–24). It seems
likely that previous work reporting a dominant role for C5 (32–
37) may well have reduced LTB4 synthesis, thereby preventing
its action on the lung; however, the role of LTB4 was not exam-
ined in these studies.
We find it interesting that natural selection has not excluded
binding of a variety of unbranched fatty acids by ectoparasite-
FIGURE 10. OmCI does not inhibit cleavage of C5a from thrombin but
does reduce the concentrationofC5a in thealveolar space.A, assay of the
inhibitory effect of OmCI on cleavage of C5a from hC5 by human thrombin
(hT). The average background value (i.e. PBS only, blankwells) was subtracted
from all samples. Four replicates/sample (95% CI) are shown. Combined data
from two independent experiments are shown. B, C5a concentration in BALF
in each treatment group (n 8 mice/group) measured at 4 h after induction
of IC-ALI. The box plot showsmedian values, upper and lower quartiles, larg-
est and smallest observations for each group, and the single outlier in the
OVA group. Significant differences between groups, determined by analysis
of variance using Tukey’s multiple comparison of means, are indicated by
asterisked bars (*, p 0.02; **, p 0.005; ***, p 0.001).
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derived OmCI. To date these are known to include palmitoleic
acid and relatedC16-C18 fatty acids and ricinoleic acid (C18) and
the preferred ligand LTB4 (C20). The closely related tick lipoca-
lin, TSGP3, shows even greater promiscuity, binding cyclic
eicosanoids (here carbocyclic TXA2) as well as LTs (43). Both
TSGP homologues and presumably OmCI also show moder-
ately high affinity binding (KD60 nM) to AA (43). We specu-
late that by sequestering AA and possibly LTA4 (the immediate
precursor of LTB4), at sites of inflammation such as the tick
feeding site, OmCI may decrease transcellular synthesis from
AA (14, 55) of LTB4 and other proinflammatory (cysLTs and
TXA2) or LT-enhancing eicosanoids such as prostaglandins.
Thus, in addition to inhibiting TCC and signaling via the BLT1,
BLT2, C5aR, and C5L2 receptors, OmCI may decrease the
overall rate of eicosanoid synthesis at inflammatory sites.
Our current hypothesis to explain the potent activity of
OmCI in IC-ALI is that intranasally administered OmCI pre-
vents cleavage of C5 by C5 convertases on alveolar epithelial
surfaces activated via IC, thereby limiting TCC formation and
C5a activation of alveolarmacrophages and other cells via FcR
threshold modulation. We propose that C convertase-medi-
ated cleavage of C5 initiates the activation of alveolar macro-
phages, which subsequently increases the release of proteases
that activate C5 independently of C. Separately, sequestration
of LTB4 by OmCI limits the action of both convertase and
non-C protease (e.g. thrombin)-derived C5a, which recruit leu-
kocytes, and in particular tissue damaging neutrophils, both
directly through C5aR and via the LTB4 receptors BLT1 and
BLT2 (22, 56). The direct and indirect actions of these co-de-
pendent systems (15, 21–24, 57) are summarized in Fig. 11. At
FIGURE 11. Interactions and feedbackmechanisms betweenOmCI, complement, Fc receptors, and LTB4 in early phase ofmouse IC-ALI. A, simplified
viewof co-dependent proinflammatory pathways focusedon alveolarmacrophages (AM) in the alveolar space in the absenceofOmCI.B, the samepathways
as inAwithOmCI present. For clarity, inflammatorymediators stimulatedby TCC, C5a, and LTB4 and cellular responseswithin the lungarenot shown.Note that
only the LTB4 receptor BLT1 is shown, as BLT2 expression inmice is restricted tomast cells and keratinocytes. The C5a receptor C5L2 is omitted from the figure,
as its actions are subject to debate. Blue arrow, stimulatory pathway; red line, inhibitory pathway. Solid line, full activation of pathway; dotted line, partial
activation of pathway.
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present we do not know whether intranasally administered
OmCI is able to enter tissue and prevent the action of C and
LTB4 within the lung or whether it acts entirely at the epithelial
surface. Future studies should examine the effect of OmCI on
FcR and additional pro- and anti-inflammatorymediators and
clarify the site at which OmCI acts, as this may have a direct
bearing on the optimal route of administration. Investigating
the elaboration of the immune response via chemokines and
cytokines induced by C5 activation and LTB4 using OmCI
mutants able to bind only C5 or LTB4 might more fully eluci-
date the downstream effects of these two mediators.
In conclusion, our data highlight the need to evaluate the
functions of LTB4, and possibly other eicosanoids, more closely
in IC-ALI and to reevaluate the relative importance of C5a
derived by complement-dependent and -independent path-
ways in C3-sufficient mice. The data show that dual inhibition
of C5 activation and LTB4 can have a profound inhibitory effect
on inflammation and in particular on neutrophil recruitment
and activation. Therapeutic indications for OmCI, or other
combined inhibitors of C5 and LTB4, may include acute forms
of immune complex-mediated diseaseswith neutrophil-depen-
dent tissue injury, such as transfusion-relatedALI, sepsis, rheu-
matic fever, and some forms of rheumatoid arthritis, peritoni-
tis, and glomerulonephritis (58). The potential therapeutic
value of dual acting drugs is widely recognized by the pharma-
ceutical industry, where there is currently intense interest in
bispecific Ab (59). Notably, the functional independence of the
two binding activities of OmCI and the detailed structural
understanding of fatty acid binding that we have described will
enable protein engineering for the selective targeting of eico-
sanoids most relevant to treatment of specific pathologies.
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